Efficacy and Safety of LAS 34273 in Patients With Moderate to Severe Stable Chronic Obstructive Pulmonary Disease (COPD).

Trial Profile

Efficacy and Safety of LAS 34273 in Patients With Moderate to Severe Stable Chronic Obstructive Pulmonary Disease (COPD).

Completed
Phase of Trial: Phase III

Latest Information Update: 18 Nov 2016

At a glance

  • Drugs Aclidinium bromide (Primary)
  • Indications Chronic obstructive pulmonary disease
  • Focus Registrational; Therapeutic Use
  • Acronyms ACCLAIM-II; ACCLAIM/COPD-II
  • Sponsors Almirall S.A.
  • Most Recent Events

    • 15 Sep 2009 Results presented at the 19th Annual Congress of the European Respiratory Society (ERS-2009)
    • 09 Sep 2009 Results from this trial will be used in support of a Marketing Authorisation Application with the European Medicines Agency in early 2010 according to an Almirall media release.
    • 18 May 2009 Results were reported at the 105th International Conference of the American Thoracic Society.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top